PainReform Ltd. has announced the completion of a strategic investment in LayerBio, Inc., acquiring a majority equity interest in the company. This investment focuses on advancing LayerBio's OcuRing™-K, a sustained-release drug delivery system aimed at managing pain and inflammation following cataract surgery. OcuRing™-K is a non-opiate, non-steroidal postoperative NSAID drug delivery system that targets the growing demand for 'dropless' solutions in ophthalmic surgery. PainReform and LayerBio plan to initiate the next clinical trial of OcuRing™-K in the U.S., aiming for FDA approval to access a high-volume, reimbursable market. The companies also intend to explore broader ophthalmic applications, including treatments for glaucoma, corneal transplants, and anti-infective uses. Results of the upcoming clinical trial have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。